"name","id","description","label","uuid:ID","rationale","instanceType"
"Study Design 1","StudyDesign_1","The main design for the study","","15a66e59-0668-4fb4-b194-aed81fba8a9f","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign"
